Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to ...

Lung cancer remains the leading cause of cancer-related mortality globally. The detection rate of nodules has significantly ...

New study warns that frequent CT scans may cause 5% of annual cancers, urging reduced usage and safer radiation doses ...

A research team led by Prof. Li Hai from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences has ...

Scientists from Colorado State University and the University of São Paulo have overcome a challenge that has prevented ...

To keep CT scan radiation doses low, Midland Memorial Hospital follows the ALARA principle: As Low As Reasonably Achievable.

The collaboration is anticipated to find new clinical pathways and aid in improving patient outcomes via imaging solutions.

Computed tomography (CT) radiation dose optimization encompasses a suite of advanced methodologies designed to minimise patient exposure to ionising radiation while preserving or enhancing ...

Consequently, SAR tomography is becoming an indispensable tool in urban mapping, environmental monitoring, and disaster management, offering robust insights where conventional imaging techniques ...

The aim of this trial is to investigate the ability of 64 Cu-SAR-bisPSMA PET/computed tomography (CT) to detect recurrence of prostate cancer, with evaluation across 2 imaging timepoints, Day 1 (day ...

Clarity has entered into a Commercial Manufacturing Agreement with SpectronRx for 64 Cu-SAR-bisPSMA. SpectronRx's facility in Indiana will provide on-demand commercial-scale manufacturing of both ...

Ultrasound CT use in intensive care units and emergency departments may soon become a reality as the result of a recent ...